November 2024
The global AI in breast imaging market size is estimated to grow from USD 480 million in 2022 to surpass around USD 734.24 million by 2032, registered at a CAGR of 3.30% between 2023 and 2032, as a result of the rise in breast cancer prevalence and rising technological advancements.
Unlock Infinite Advantages: Subscribe to Annual Membership
According to the National Health Institute, the Substantial 43% Decline in Female Breast Cancer Mortality from 1989 to 2020 is a Major Achievement, with Early Detection and the growth of AI in the Breast Imaging Market Driven by High Innovation.
Artificial intelligence has significantly progressed in various fields, essential to breast imaging. Using machine learning and deep learning, AI analyses huge amounts of data to enhance breast health care in four main areas: Screening, detection, diagnosis, disease monitoring and overall data management. Breast cancer, a significant global health challenge, has been the top cause of cancer-related death among women.
In 2020, according to the World Health Organization, it was estimated that 684,996 women lost their lives because of breast cancer, making up 15.5% of all cancer cases in women. AI is making strides in managing clinical data, detecting uncertain cases, predicting outcomes, and organizing data for better clinical decisions.
The advent of promising imaging techniques, such as mammograms, has transformed the treatment of cancer management. Early detection of breast cancer through mammograms, coupled with advanced treatment, has demonstrated a reduction in mortality. The imperative for early detection is underscored, and the integration of AI in breast imaging emerges as a pivotal solution. This growing awareness of the importance of early detection through AI has catalyzed a surge in demand, significantly expanding the Global Market in breast imaging. Artificial intelligence techniques, specifically in Machine Learning and deep learning, have shown impressive advancements in various fields. Deep learning, a subset of machine learning, has recently been shown in multiple studies to outperform traditional expert-oriented methods when compared to ground truth labels and, in certain task-specific scenarios, to surpass them. Despite its data-hungry nature, deep learning provides thorough management and correlation of concentrated multivariate data, which may have infinite cross-data/case referencing possibilities. For this reason, radiomics' concentrated semantic data, which essentially describe the radiographic aspect of the breast, makes for a highly scientific resource that would be perfect for training a deep learning model.
The application of AI in Breast Imaging has driven advancement by improving diagnostic accuracy, enabling early detection of abnormalities, and enhancing overall efficiency in healthcare processes. AI algorithms assist in analyzing complex imaging data, adding healthcare professionals to make more accurate and timely decisions, ultimately contributing to improved patient outcomes.
Breast cancer is a prevalent global health concern, ranking among the most common cancers worldwide, according to the World Health Organisation (WHO). Breast cancer is the most frequent cancer in women, impacting both developed and developing countries. The prevalence of breast cancers varies geographically and is influenced by factors such as age, genetics, hormonal influences and lifestyle.
For Instance, according to the American Cancer Society 2023 estimates, invasive breast cancer will be diagnosed in women in about 297,790 new cases. There will be roughly 55,720 new diagnoses of Ductal Carcinoma In situ (DCIS). There will be 43,700 female breast cancer deaths.
The prevalence underscores the critical need for early diagnosis, as timely intervention significantly improves treatment outcomes and survival rates. Early detection of breast cancer is crucial for several reasons:
| Improve Treatment Efficacy | Detecting breast cancer at an early stage allows for less aggressive and more effective treatment options. Physical and emotional impact on individuals. This contributes to an improved overall quality of life for breast cancer patients. |
| Reduce Mortality Rate | Early diagnosis substantially decreases the mortality rate associated with breast cancer. |
| Enhance Quality of Life | Early detection, less invasive treatment approaches, minimising the physical and emotional impact on individuals. This contributes to an improved overall quality of life for breast cancer patients. |
The importance of early diagnosis has driven advancement in medical technologies, including AI in breast imaging. AI plays an important role in increasing the accuracy and efficiency of breast cancer detection.
Additionally, awareness has grown regarding the significance of early breast cancer detection and the role of AI in improving diagnostic capabilities; there has been a notable increase in the market demand for AI in breast imaging. The integration of AI technologies enhances diagnostic accuracy and almost supports the healthcare system in managing the rising volume of breast screening, thereby contributing to the overall growth of the AI in the breast imaging market.
In 2021, the National Institute of Health released an article about More than 20 FDA-approved AI applications for breast imaging resulting from recent advancements. However, they are only sometimes adopted, and their overall utilization could be higher. AI development faces particular opportunities and challenges in the field of breast imaging. The primary form of breast cancer screening is mammography. Application of artificial intelligence, breast density measurement, workflow enhancement, quality assessment, treatment response evaluation, and image enhancement.
The trend toward early detection is attributed to improvements in treatment, increased public awareness of the disease, and earlier detection through breast cancer screening. Next-generation technology advancements are essential for sensitive, accurate, and reasonably priced healthcare. Although biomarkers such as DNA, RNA, Protein, and epigenetics contribute to our understanding of breast cancer, their worldwide non-reproducibility limits their applicability. The best form of prevention is awareness; formalized screening programs are essential to empowering women via self-screening and education. Individuals at high risk can benefit from clinical consultations and counselling.
Moreover, innovation and teamwork are closely associated with the growth of the AI imaging market. The use of artificial intelligence in medical imaging has increased dramatically due to strategic alliances and partnerships. This cooperative approach offers a promising synergy between medical knowledge and cutting-edge technology, improving diagnostic capabilities and playing a critical role in the ongoing fight against breast cancer.
Secure laws are essential protections for patient safety, data security, and the dependability of medical equipment in the healthcare sector. These rules become a safeguard as well as a significant obstacle when it comes to incorporating AI in breast imaging. Healthcare regulations are intended to ensure the moral application of technology in medical settings. Stringent compliance requirements frequently typify them. Compliance in the context of AI applications for breast imaging refers to adhering to guidelines for patient confidentiality, data privacy, and the general safety of the AI algorithms. The safeguarding of private patient information is one important factor. Large datasets, such as patient records and medical images, are frequently the basis for AI systems used in breast imaging. Complying with data privacy regulations, like the US Health Insurance Portability and Accountability Act (HIPAA), complicates the integration process. It is crucial to ensure AI Applications handle patient data securely and keep it private.
Additionally, safety regulations are essential for AI systems employed in medical diagnosis. Regulatory bodies frequently demand thorough validation to prove the accuracy, consistency, and dependability of AI algorithms. Extensive testing on various datasets is part of this validation process to ensure the AI system works well in a range of scenarios and demographics. To successfully navigate these regulatory obstacles, great care must be taken during the development, testing, and implementation stages of AI solutions for breast imaging. The extensive validation process and strict adherence to compliance guidelines add to the implementation's time-consuming complexity. Companies and developers must spend money on clinical trials, regulatory approvals, and system optimization to meet stringent requirements—the more extended time frames for releasing AI solutions on the market result from these regulatory obstacles. Implementation delays may impact the overall rate of advancement in AI technologies for breast imaging. The complexity of compliance procedures has grown, making things more complicated overall, especially for smaller businesses with fewer resources.
Furthermore, strict healthcare laws are necessary to preserve the accuracy of medical technologies, but they also create barriers to the quick adoption of AI in breast imaging. To fully utilize AI's potential to improve breast cancer detection and diagnosis, stakeholders must balance innovation and compliance.
These factors collectively contribute to the growth of AI in the breast imaging market. Collaboration between hospitals, diagnostic imaging centres, and research institutes fosters an environment where technology continually evolves and proves its value in enhancing breast imaging capabilities. As a result, the market experiences sustained growth driven by the collective efforts to improve efficiency, workflow, and the accuracy of breast imaging through AI applications.
In 2022, North America was the dominant market for Artificial Intelligence in breast imaging. The growth in this market is attributed to the increasing incidence of breast cancer in the region.
For Instance, according to the American Cancer Society of Clinical Oncology, the U.S. alone is estimated to have 287850 new cases of invasive breast cancer, 51,400 cases of DCIS and 43,250 breast cancer-related deaths among women in 2022.
The impact on market expansion is due to the high prevalence of breast cancer in the U.S., which is expected to drive the expansion of the breast imaging industry in North America.
The global artificial intelligence in breast imaging market is expected to experience its fastest expansion in the Asia-Pacific region. The rising incidence of breast cancer is a significant and responsible factor that propels market growth.
For Instance, according to the Centers for Disease Control and Prevention, breast cancer is the most common malignancy in most Asian nations, irrespective of race or ethnicity. Significant research and development expenditures on breast cancer treatment contribute to market expansion. Advancement in breast imaging technologies plays a role in driving the market forward.
The AI in breast imaging offers transformative opportunities across healthcare. AI enhances early detection and diagnosis by improving accuracy through efficient analysis, facilitating timely intervention in breast cancer cases. In personalized medicine, AI analyzes patient history, genetics, and imaging data to tailor treatment plans, optimizing outcomes. Workflow efficiency is boosted as AI automates tasks in breast imaging, streamlining processes, aiding prioritization, and reducing interpretation times. AI's contribution to research and development lies in its ability to conduct sophisticated analyses of large datasets, advancing the understanding and treatment of breast cancer. AI assists medical professionals in training and education by providing simulations that refine diagnostic skills. The increasing demand for AI in breast imaging fuels market growth and presents investment opportunities for healthcare technology and AI development companies. Additionally, AI's complexity fosters collaborations between technology firms, healthcare providers, and research institutions, accelerating the development and deployment of AI in breast imaging.
By Component Type
By Imaging Modality
By Application
By End User
By Geography
November 2024
November 2024
November 2024
November 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts